Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Get up and eat: a new approach to speed lung surgery recovery?

NCT ID NCT07749950

Disease control Sponsor: Ege University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether starting to eat and move soon after lung cancer surgery (lobectomy) can improve recovery. Half of the participants will follow an enhanced recovery protocol, sitting up and walking within hours of surgery and starting liquids early, while the other half receives standard care. Researchers will compare pain, complications, chest tube duration, hospital stay, and quality of life over three months to see if this faster approach helps patients bounce back sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Early mobilization and early oral feeding (ERAS protocol components)
What this could lead to
If effective, this approach could shorten hospital stays, reduce complications, and speed recovery for lung cancer patients after lobectomy surgery.
What could go wrong
This is a small, single-center trial, and results may not apply broadly. Early activity and eating might not be safe or beneficial for all patients, and there is a risk of complications like intolerance to food or falls.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis or suspected diagnosis of lung cancer, including: 1. Histologically or cytologically confirmed lung cancer 2. Radiologically suspected lung cancer pending pathological confirmation * Scheduled to undergo lobectomy * Eastern Cooperative Oncology Group (ECOG) performance status of: 1. ECOG 0 2. ECOG 1 * Ability and willingness to participate, including: 1. Voluntary agreement to participate 2. Ability to provide written informed consent Exclusion Criteria: * Requirement for emergency surgery * Metastatic disease * Severe uncontrolled comorbid disease, including: 1. Cardiac failure 2. Renal failure 3. Hepatic failure * Requirement for mechanical ventilation for 24 hours or longer * History of cranial trauma * Requirement for prolonged bed rest * Neurological conditions, including: 1. Local peripheral neuropathy 2. Central nervous system disease * Impairment affecting participation, including: 1. Cognitive impairment 2. Communication impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung neoplasms

Contacts and locations

Locations

  • Ege University Hospital, Department of Thoracic Surgery

    Izmir, 35100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.